Arizona State Retirement System Sells 115 Shares of Amedisys, Inc. (NASDAQ:AMED)

Arizona State Retirement System lowered its stake in Amedisys, Inc. (NASDAQ:AMED) by 1.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,388 shares of the health services provider’s stock after selling 115 shares during the period. Arizona State Retirement System’s holdings in Amedisys were worth $870,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Norges Bank acquired a new stake in Amedisys during the 4th quarter worth $83,061,000. Pentwater Capital Management LP grew its holdings in Amedisys by 178.3% during the 4th quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider’s stock worth $107,132,000 after acquiring an additional 756,000 shares during the period. AQR Arbitrage LLC grew its holdings in Amedisys by 59.1% during the 4th quarter. AQR Arbitrage LLC now owns 471,965 shares of the health services provider’s stock worth $42,812,000 after acquiring an additional 175,311 shares during the period. Toronto Dominion Bank acquired a new position in shares of Amedisys in the 4th quarter valued at $15,801,000. Finally, CIBRA Capital Ltd grew its holdings in shares of Amedisys by 359.7% in the 1st quarter. CIBRA Capital Ltd now owns 216,775 shares of the health services provider’s stock valued at $20,080,000 after buying an additional 169,616 shares during the period. Institutional investors and hedge funds own 94.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Amedisys from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 24th. Royal Bank Of Canada reissued an “outperform” rating and issued a $100.00 price target on shares of Amedisys in a report on Wednesday, April 16th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $100.75.

Amedisys Price Performance

NASDAQ:AMED opened at $97.46 on Monday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.29 and a current ratio of 1.29. The stock’s 50-day simple moving average is $96.01 and its 200 day simple moving average is $93.77. The company has a market cap of $3.20 billion, a P/E ratio of 35.96, a P/E/G ratio of 1.32 and a beta of 0.94. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.12. The business had revenue of $594.78 million during the quarter, compared to the consensus estimate of $597.43 million. Amedisys had a net margin of 3.79% and a return on equity of 12.52%. Amedisys’s revenue was up 4.1% on a year-over-year basis. During the same period last year, the business posted $1.03 EPS. As a group, sell-side analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.